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Abstract
Background: Although oxidative stress by accumulation of reactive oxygen species (ROS) in
diabetes has become evident, it remains unclear what genes, involved in redox balance, would
determine susceptibility for development of atherosclerosis in diabetes. This study evaluated the
effect of genetic polymorphism of enzymes producing or responsible for reducing ROS on coronary
artery calcification in type 2 diabetes (T2D).
Methods: An index for coronary-arteriosclerosis, coronary artery calcium score (CACS) was
evaluated in 91 T2D patients using a multi-slice computed tomography. Patients were genotyped
for ROS-scavenging enzymes, Glutathione peroxidase-1 (GPx-1), Catalase, Mn-SOD, Cu/Zn-SOD, as well
as SNPs of NADPH oxidase as ROS-promoting elements, genes related to onset of T2D (CAPN10,
ADRB3, PPAR gamma, FATP4). Age, blood pressure, BMI, HbA1c, lipid and duration of diabetes were
evaluated for a multivariate regression analysis.
Results: CACS with Pro/Leu genotype of the GPx-1 gene was significantly higher than in those with
Pro/Pro (744 ± 1,291 vs. 245 ± 399, respectively, p = 0.006). In addition, genotype frequency of
Pro/Leu in those with CACS ≥ 1000 was significantly higher than in those with CACS < 1000 (45.5%
vs. 18.8%; OR = 3.61, CI = 0.97–13.42; p = 0.045) when tested for deviation from Hardy-Weinberg's
equilibrium. Multivariate regression analyses revealed that CACS significantly correlated with GPx-
1 genotypes and age.
Conclusion: The presence of Pro197Leu substitution of the GPx-1 gene may play a crucial role in
determining genetic susceptibility to coronary-arteriosclerosis in T2D. The mechanism may be
associated with a decreased ability to scavenge ROS with the variant GPx-1.
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Background
Evidence from large-scale clinical trials such as the Multi-
ple Risk Factor Trial (MRFIT) [1] and the Hisayama study
[2] demonstrates that mortality from coronary artery dis-
ease in patients with type 2 diabetes (T2D) is three to five
times higher than in individuals with normal glucose tol-
erance. Therefore, existence of coronary artery disease
should be considered as an adverse prognostic factor for
patients with T2D. Thus, elucidation of the mechanism by
which atherosclerosis occurs and develops in patients
with T2D will lead to improving the prognosis of T2D
patients.
Atherosclerosis is a multi-factorial disorder. Even if T2D
patients are exposed to hyperglycemia to the same degree,
two types of individuals can be observed; one in whom
arterial sclerosis develops strongly and the second group
in whom arterial sclerosis remains minor. Genetic suscep-
tibility is thought to be the factor determining the onset of
disease in those affected by hyperglycemia, especially the
condition in which strong accelerators such as reactive
oxygen species (ROS) accumulate. Tissue damage medi-
ated by ROS, or oxidative stress, is implicated as a poten-
tial molecular mechanism leading to the development of
atherosclerosis [3]. It is particularly important to maintain
the redox milieu by balancing production and degrada-
tion of ROS, the so-called redox balance. This balance can
be altered by either a reduction in the ability to degrade
ROS but also by an increase in ROS production, resulting
in excess ROS accumulation, inducing a redox imbalance,
ultimately leading to tissue injury.
There are many studies focusing on the mechanism
responsible for ROS overproduction but few of these have
investigated the whole mechanism of redox balance. It is
important to answer the question whether the degree of
arterial sclerosis progresses strongly in diabetic subjects
with genetic characteristics associated with low ROS deg-
radation. Therefore, we thought it would be helpful for
identification of the potentially susceptible genes to
examine SNPs of genes involved in ROS metabolism in
patients with T2D.
In this study, we examined T2D patients and evaluated
their degree of coronary artery calcification by coronary
artery calcium score (CACS) using multi-slice computed
tomography (MSCT), which could provide highly quanti-
tative evaluation of the degree of progression of arterio-
sclerosis. We investigated the relationship between CACS,
and the redox-related genes and the genes associated with
the onset of T2D to clarify the role of these genes in the
mechanisms responsible for the onset of atherosclerosis
in T2D.
Methods
Patients and clinical evaluation
Ninety-one patients with T2D (65 men and 26 women;
mean age, 59 years; mean disease duration, 11.9 years)
were enrolled in this study from November 2003 to
December 2005. Patients were admitted to the Hospital of
the Division of Diabetes Metabolism and Endocrinology
at Jikei University School of Medicine, Tokyo, Japan.
Patients with T2D were diagnosed in accordance with the
Japan Diabetes Society criteria, and were treated by either
diet alone, oral agents or insulin. The study protocol was
approved by the Ethics Committee of the Jikei University
School of Medicine. Written informed consent was
obtained from all patients before their participation in the
study.
Medical history including family history, smoking status
and duration of diabetes were recorded. Gender, body
mass index (BMI) and blood pressure were also recorded.
Fasting blood was examined for total cholesterol, triglyc-
eride, HDL-cholesterol, plasma glucose, and HbA1c val-
ues.
Determination of coronary artery calcification
The intensity and the extent of coronary artery calcifica-
tion was determined by 16-slice MSCT (SOMATOM Sen-
sation 16; Siemens Medical Solutions, Germany). Cardiac
image data for coronary scan was acquired with retrospec-
tive ECG gating. The range of the entire heart was covered
within a single breath hold (15–20 seconds). The rotation
speed of the gantry was set as 0.42 sec/rotation and the
helical pitch was set as 2.8. For image reconstruction, the
slice thickness was set as 3.0 mm for quantification of
CACS. CACS was calculated according to the algorithm
suggested by Agaston et al as follows [4][5]. First, an area
of interest was set in the calcification area of the coronary
artery in each slice, and the calcification was considered
significant when the CT value was 130 Hounsfield Units
or over and the calcification area was 0.51 mm2 (two pix-
els) or over. The highest CT value in each area, including
significant calcification was weighted as 130–199HU = 1,
200–299HU = 2, 300–399HU = 3 and 400HU or over = 4.
The calcification score in the area was obtained by multi-
plying the calcification area by the assigned weight, and
the total calcification score in each area was the calcifica-
tion score for the patient.
Genotyping
In this study, we analyzed a total of 9 genes for the follow-
ing two categories (Table 1): (a) genes to be associated
with the onset of T2D and/or insulin resistance; and (b)
genes for enzymes involved in the production and degra-
dation of ROS. Genomic DNA was extracted from periph-
eral blood using FlexiGene (Qiagen, Hilden, Germany)Cardiovascular Diabetology 2007, 6:23 http://www.cardiab.com/content/6/1/23
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following the manufacture's protocol. All single nucle-
otide polymorphisms (SNPs) were determined using
PCR-RFLPs method: the Pro197Leu variant ascribed to the
cSNP in exon 2 of the Glutathione peroxidase-1 (GPx-1)
gene (rs1050450) [6], the A/T variation at position -89 in
the promoter region of the Catalase gene [7], the Ala16Val
variant in exon 2 of the Mn-SOD gene (rs4880) [8], the A/
C substitution at position -34 in intron 3 of the Cu/Zn-
SOD gene [9], the C/G variation at position +242 in exon
4 of the NADPH oxidase gene; Cytochrome b light chain
(CYBA) gene (rs4673) [10], the A/G intronic iSNP of the
Calpain 10 (CAPN10) gene (rs3792267) [11], the
Try64Arg variant in exon 1 of the β3-adrenergic receptor
(ADRB3) (rs4994) [12], the Pro12Ala variant in exon 1 of
the  Peroxisome proliferator activated receptor γ  (PPARγ)
(rs1801282)[13] and the Gly209Ser variant in exon 3 of
the  Fatty acid transport protein-4 (FATP4) (rs2240953)
[14]. The oligonucleotides and the restriction enzymes
used for the PCR-RFLPs are shown in Table 1.
DNA amplification was carried out in a final volume of 20
μL, using 0.1 μg of genomic DNA and 1 nmol each of the
primers. The four deoxynucleotides were included in a
final concentration of 100 μmol/L. The reaction buffer
was prepared as recommended by the manufacturer. The
amplification reaction was started by adding 0.5 units of
Taq polymerase (TAKARA, Japan). Annealing, extension
and denaturing were carried out using an automatic ther-
mal cycler (DNA Engine®, Bio-RAD, Japan). The amplified
products were digested at 37 or 60°C for 1 hour using 25
μL of each PCR-amplified product with 10 units of the
restriction enzyme (New England Biolabs, Inc., MA, USA
and TAKARA, Japan). The digested products were then
electrophoresed at 100V for one hour through a 3.5% aga-
rose gel. The gels were stained with ethidium bromide and
visualized by ultraviolet light to determine the SNPs.
Analysis of genetic association
The CACS values were tested for differences among the
patients with different genotypes of all candidate genes by
the Student's t-test. Contribution of BMI, age, gender,
duration, HbA1c, systolic blood pressure and LDL-choles-
terol related to CACS was also evaluated by the multivari-
ate regression analysis. The Student's t-test and the
multivariate regression analyses were performed using Dr.
SPSS II (SPSS, Chicago, IL, USA). P < 0.05 was considered
to be statistically significant. Allele and genotype frequen-
cies of cases (CACS ≥ 1,000) and controls (CACS < 1,000)
were compared with values predicted by Hardy-Wein-
berg's equilibrium (HWE) using the χ2 test. For this pur-
Table 1: List of sequences of PCR primers used
a.
Gene Restriction 
Enzyme
Direction Primers
CAPN10 (A/G-iSNP43) Nsp I Sense 5' GCTGGCTGGTGACATCAGTG3'
Antisense 5' TCAGGTTCCATCTTTCTGCCAG3'
ADRB3 (Try64Arg) Mva I Sense 5' CGCCCAATACC-GCCAACAC3'
Antisense 5' CCACCAGGAGTCCCATCACC3'
PPARγ (Pro12Ala) Bst UI Sense 5' GCCAATTCAAGCCCAGTC3'
Antisense 5'GATATGTTTGCAGACAGTGTATCAGTGAAGGAA
TCGCTTTCCG3'
FATP4 (Gly209Ser) Hpa II Sense 5' GTGAGGTCCATGCCAGCCTG3'
Antisense 5' CACCTGTGAAGCCCTTGGTCAG3'
b.
Gene Restriction 
Enzyme
Direction Primers
GPx-1 (Pro197Leu) Hae III Sense 5' TTATGACCGACCCCAAGCTCA3'
Antisense 5' ACAGCAGCACTGCAACTGCC3'
Catalase (SNP-89) Hinf I Sense 5'AATCAGAAGGCAGTCCTCCC3'
Antisense 5'TCGGGGAGCACAGAGTGTAC3'
Mn-SOD (Ala16Val) BsaW I Sense 5' GCTGTGCTTTCTCGTCTTCAG3'
Antisense 5'TGGTACTTCTCCTCGGTGACG 3'
Cu/Zn-SOD (intron 3) Hha I Sense 5'CTATCCAGAAAACACGGTGGGCC3'
Antisense 5'ATTGCCCAAGTCTCCAACATGC 3'
NADPH oxidase (+242) Rsa I Sense 5'ACACTGAGGTAAGTGGGGGTGGCTCCTGT3'
Antisense 5' TGCTTGTGGGTAAACCAAGGCCGGTG3'
Oligonucleotides used as PCR primers for the detection of each SNP. a) genes associated with the onset of type 2 diabetes and/or insulin 
resistance. b) genes related to the ROS-scavenging system. Enzymes represent restriction enzymes for detection of each RFLP of PCR product.Cardiovascular Diabetology 2007, 6:23 http://www.cardiab.com/content/6/1/23
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pose, the frequency of the GPx-1  variant (Pro197Leu)
allele and the genotype with Pro/Leu at the 197 position
were compared between the controls and the cases. Calcu-
lation for the case-control study was performed using the
DeFinetti computer program http://ihg.gsf.de/cgi-bin/
hw/hwa1.pl. All values in clinical tests were presented as
mean ± SD.
Results
Clinical characteristics of the patients are summarized in
Table 2. In the genetic association study, our aim was to
know whether the CACS would be different according to
the genotypes of each gene. When compared among gen-
otypes, the observed CACS showed no significant differ-
ence except at position 197 of the GPx-1  gene where
proline is the major allele and leucine is the minor allele,
as shown in Table 3. Heterozygotes with Pro197Leu of the
GPx-1 gene had significantly higher CACS than homozy-
gotes of proline allele (744 ± 1,291 vs. 245 ± 399, respec-
tively, p = 0.006). This result shows a possibility that the
Pro197Leu variation of the GPx-1 gene is genetically asso-
ciated with an increase in CACS, or acts as a marker for
coronary sclerosis. Significant differences in CACS of Pro/
Leu at position 197 of GPx-1 also suggest that the genetic
mode is dominant. There was no significant difference in
the clinical characteristics between patients with Pro/Pro
and Pro/Leu (Table 4). Confounding factors were further
examined for association with CACS by multiple regres-
sion analysis where the dependent variable was CACS,
and the explanation variables were clinical parameters
and candidate genes. The results of the analysis also
showed a significant correlation between CACS and two
variables: GPx-1 genotype (standardization coefficient =
0.340, p = 0.004) and age (standardization coefficient =
0.257, p = 0.042).
In order to confirm the genetic association between CACS
and the GPx-1 gene, we next conducted a case-control
study based on Hardy-Weinberg's law, comparing the
genotype frequencies in accordance with the CACS value.
When the patients were stratified by CACS as shown in
Table 5a, a significant difference in distribution of the
genotype frequency for the Pro197Leu cSNP at GPx-1
gene was observed. The frequency of the Pro/Leu hetero-
zygote among the cases (CACS values ≥ 1,000) was signif-
icantly higher than that among the controls (CACS values
< 1,000) (OR = 3.61; CI = 0.97 – 13.4; p = 0.045). Analysis
for differences in the allelic distribution also revealed the
same tendency (Table 5b, p = 0.06).
Discussion
It has been established that patients with coronary artery
calcification evaluated by MSCT are at high risk for coro-
nary events [15]. As prevalence of coronary artery calcifi-
cation and coronary events are significantly greater among
patients with T2D than the non-diabetic controls [16], the
mechanism and the traditional risk assessment for coro-
nary atherosclerosis in patients with T2D must be refined.
Atherosclerosis appears to be a multifactorial disorder, in
which the classical Framingham factors, aging and poorly
controlled diabetes are independent risk factors for the
development of atherosclerosis. However, it is still not
easy to identify genetic factors for atherosclerosis among
their confounding components even though knowledge
of the human genome project has been established. In our
attempt to identify genes associated with coronary artery
sclerosis, we analyzed genes involved in the pathogenesis
for development of T2D as well as genes of enzymes that
are pertinent to determination of the redox balance. The
sample size of this report was limited as a genetic associa-
tion study because the X-ray examination was a prerequi-
site for participation. However, our present study is
unique in that the predisposition for coronary artery scle-
rosis by altered function in redox-related genes was ana-
lyzed with using MSCT-assisted calcium scoring
combined with known risk factors. MSCT-assisted evalua-
tion of CACS represents now a standard index indicating
intensity and extent of the coronary atherosclerosis in rou-
tine clinical practice. In addition to the calcifications, the
atherosclerotic plaque and the obstructive lesion in coro-
nary artery are major issues with the latest 64-MSCT. It
would be interesting to investigate which observation
including the properties of the plaque, calcifications and
stenosis is strongly associated with the GPx-1 polymor-
phism as the information should provide further insights
into the mechanism for development of coronary athero-
sclerosis.
There is growing evidence that excess generation of highly
reactive free radicals, largely due to hyperglycemia, causes
oxidative stress, which further exacerbates the develop-
ment and progression of diabetes and its complications.
Overproduction and/or insufficient removal of these free
Table 2: Clinical characteristics of patients with type 2 
diabetes.
Age (years) 60 ± 8 (range, 42 – 81)
Duration of diabetes (years)
BMI (kg/m2)
11.6 ± 8.9 (range, 0 – 42)
24.4 ± 3.7
LDL-cholesterol (mmol/l) 3.37 ± 0.81
HDL-cholesterol (mmol/l) 1.31 ± 0.55
Triglyceride (g/l) 1.69 ± 1.15
Blood pressure (systolic) 
(mmHg)
137 ± 18
Blood pressure (diastolic) 
(mmHg)
80 ± 11
HbA1c (%) 8.2 ± 1.8
Smoking 40/91 (44.0%)
Data are mean ± standard deviation (SD) or frequencies (%).Cardiovascular Diabetology 2007, 6:23 http://www.cardiab.com/content/6/1/23
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radicals result in vascular dysfunction, damage to cellular
proteins, membrane lipids and nucleic acids [17]. GPx-1
represents the first identified mammalian selenoprotein
[18], and our understanding in the metabolic regulation
and function of this abundant selenoenzyme has greatly
advanced during the past decade [19]. However, GPx-1
exerts a dual role in reactive nitrogen species (RNS)-
related oxidative stress [20]. Intracellular and tissue levels
of GPx-1 activity affect apoptotic signaling pathway, pro-
tein kinase phosphorylation, and oxidant-mediated acti-
vation of NFkappaB. Data are accumulating to link
alteration or abnormality of GPx-1 expression to etiology
of cardiovascular disease and diabetes [21]. The develop-
ment of insulin resistance in mammals with elevated
expression of an antioxidant enzyme and suggest that
increased GPx-1 activity may interfere with insulin func-
tion by overquenching intracellular reactive oxygen spe-
cies required for insulin sensitizing [22].
Results from our multivariate analysis and association
study revealed the polymorphism of GPx-1  gene to be
associated with MSCT-detected CACS on all the tested ele-
ments except aging. It has been reported that low activity
in the GPx-1 of red blood cells is associated with an
increased risk for the onset of cardiovascular events [23].
In addition, low activity in GPx-1 has also been impli-
cated in promoting calcification of coronary arterial walls.
More importantly, a recent paper investigating the com-
mon variant Pro197Leu of GPx-1 reported this variant to
be associated with a 40% decrease in activity [24]. GPx-1
is expressed in endothelial cells and macrophages of nor-
mal and atherosclerotic vessels [25]. Therefore, individu-
als having the Pro197Leu variant at GPx-1 are assumed to
have a genetically low level of GPx-1 activity at vascular
Table 4: Clinical characteristics of patients with Pro/Pro and Pro/
Leu at GPx-1 gene.
Pro/Pro Pro/Leu p value
Age(years) 59.4 ± 8.3 62.7 ± 8.9 0.136
Duration of diabetes(years) 11.3 ± 8.5 12.5 ± 8.8 0.609
BMI(kg/m2) 24.7 ± 3.9 24.2 ± 3.1 0.596
LDL-cholesterol(mmol/l) 3.39 ± 0.80 3.39 ± 0.83 0.978
HDL-cholesterol(mmol/l) 1.32 ± 0.65 1.31 ± 0.55 0.679
Triglyceride(g/l) 1.71 ± 1.16 1.63 ± 1.16 0.809
Blood pressure (systolic) 
(mmHg)
138 ± 19 132 ± 13 0.208
Blood pressure (diastolic) 
(mmHg)
81 ± 12 76 ± 8 0.119
HbA1c (%) 8.5 ± 1.8 7.8 ± 1.6 0.158
Smoking (%) 43.1 63.7 0.272
Data are means ± standard deviation (SD) or frequencies (%).
Table 3: Results of association analyses between each genotype of candidate genes and coronary artery calcium score (CACS).
a.
Gene (SNPs) Genotype No. of patients CACS (HU) p value
CAPN10 (A/G-iSNP43) G/G 84 (92.3%) 362 ± 735 0.456
G/A 7 (7.7%) 153 ± 150
ADRB3 (Try64Arg) Try/Try 55 (61.8%) 377 ± 776 0.621
Arg/Arg & Arg/Try 34 (38.2%) 301 ± 605
PPARγ (Pro12Ala) Pro/Pro 85 (93.4%) 335 ± 686 0.580
Ala/Pro & Ala/Ala 6 (6.6%) 502 ± 1049
FATP4 (Gly209Ser) Gly/Gly 48 (52.7%) 346 ± 797 0.991
Ser/Ser & Ser/Gly 43 (47.3%) 346 ± 605
b.
Gene (SNPs) Genotype No. of patients CACS (HU) p value
GPx-1 (Pro197Leu) Pro/Pro 71 (78.0%) 245 ± 399 0.006 *
Pro/Leu 20 (22.0%) 744 ± 1291
Catalase (SNP-89) T/T 25 (27.5%) 319 ± 573 0.821
A/T & A/A 66 (72.5%) 357 ± 758
Mn-SOD (Ala16Val) Val/Val 49 (55.7%) 293 ± 669 0.440
Val/Ala & Ala/Ala 39 (44.3%) 408 ± 756
Cu/Zn-SOD (intron 3) C/C 34 (37.4%) 370 ± 788 0.805
C/A & A/A 57 (62.6%) 332 ± 664
NADPH oxidase (exon 4) C/C 79 (86.8%) 311 ± 724 0.224
T/T & T/C 12 (13.2%) 579 ± 567
Difference of CACS according to each genotype of candidates genes. a) genes that are associated with onset of type 2 diabetes. b) genes that are 
related to the redox balance. Student t-test; * : p < 0.05.Cardiovascular Diabetology 2007, 6:23 http://www.cardiab.com/content/6/1/23
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wall and hence their vessels may be sensitive to oxidative
stress. This may be attributable to the observed associa-
tion between patients with the Pro197Leu variant and
higher CACS in our present study.
Non-diabetic individuals were not examined in this study;
but the multivariate analysis and the association study
among T2D patients revealed a significant association
between CACS and GPx-1 polymorphism. It has almost
been established that production of ROS in patients with
diabetes becomes excessive and results in oxidative stress.
This may account for the observed association between
CACS and the gene of the ROS-scavenging GPx-1 in T2D
patients in spite of the lack of association with polymor-
phisms of the ROS-promoting enzymes. Further study
could reveal a possibility of intervention to prevent
atherosclerosis among T2D patients by adding sufficient
activity of GPx-1.
Conclusion
This study revealed a genetic association between the pres-
ence of the Pro197Leu variant of the GPx-1  gene with
MSCT-detected coronary artery calcification. Functional
relevance of a variant for the antioxidant enzyme may
account for a critical role for changes in the redox balance
in the pathogenesis of coronary atherosclerosis in T2D
patients.
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